Connect with us

News

TaraCares agrees MIMOSA™ pilots and launches Menopause Intelligence™ Maturity Index for corporates

TaraCares aims to empower employers to design individualised workplace practices

Published

on

Jyoti Sharma, founder and CEO of TaraCares

TaraCares has announced its first MIMOSA™ pilots ahead of launching Menopause Intelligence™ Maturity Index.

TaraCares Global, the developer behind the virtual menopause health literacy and workplace wellbeing platform MIMOSA™, aims to reimagine how female individuals of all ages, ethnicities and genders navigate their unique menopause journey. 

A B2B HealthTech SaaS platform, MIMOSA™  is currently available through employers.

Individuals receive user-centric validated research continually personalised to their health profile, real-time history and health trace across 29 health variables extracted from analysing large scale high-quality research on menopause funded by Innovate UK and the National Institute for Health and Care Research (NIHR). This includes physiological and psychological health alongside other life stressors. 

MIMOSA™ enables employers to transform from Menopause Friendly to Menopause Intelligent, helping them benefit from sophisticated signals on the needs and diversity of their menopausal workforce. 

This, TaraCares argues, in turn empowers employers to design individualised workplace practices and prevent costs from support built for the average menopause experience. 

 

Already available on Android and iOS in 16 countries, the platform has received positive feedback from clinicians and individual users during the private launch that witnessed a user engagement rate of 84.38 per cent in 11 countries.

In an effort to expand, TaraCares has signed the first pilot for its MIMOSA™ platform with the Hampshire and Isle of Wight (HIOW) Integrated Care Services (ICS) beginning September 2023.

Jyoti Sharma, founder and CEO of TaraCares, said: “We are addressing the menopause health crisis by disrupting the menopause market and the enterprise software employee/people experience economy with MIMOSA™, creating a new category for menopause health literacy and workplace wellbeing.” 

Hilary Todd, project director for the Hampshire and Isle of Wight ICS Employee Health and Wellbeing Programme

Hilary Todd, project director for the Hampshire and Isle of Wight ICS Employee Health and Wellbeing Programme, which delivers health and wellbeing support and services to 55,000 NHS and primary care employees, added: “No two experiences of menopause are the same, so we are excited to offer MIMOSA™ to help our people gain personalised insights that support them in understanding and managing their menopause. 

“The pilot complements our menopause programme, which is designed to help colleagues feel more confident and ultimately more empowered. We hope that the personalised insights gained make a valuable difference for our people.” 

Evidence and feedback 

In the US$4.2tn wellness market comprising personalised medicine, healthy eating, nutrition and workplace wellbeing solutions, TaraCares has been unstoppable in integrating its academic and scientific research evidence with tech and clear pathways to value through its collaboration with the Wessex Academic Health Science Network (AHSN) and the York Health Economics Consortium (YHEC).

 

The research, design and development team behind MIMOSA

Evidence and feedback is central to TaraCares’s ethos. The company has collaborated with the Academic Health Sciences Networks (AHSN) in England to stay aligned with building for the NHS and has partnered with Gemma Snell, innovation and industry programme manager at NHS Innovation Service.

“Working with Gemma Snell as the innovation lead at the Wessex AHSN has been instrumental in critical analysis to develop MIMOSA™ further; collaborating on the value proposition, arranging market insights opportunities with GPs with special interest in menopause as well as a local NHS ICB Peoples Programme,” said Sharma. 

Gemma Snell, innovation and industry programme manager at NHS Innovation Service

Snell, who has spent over 10 years working in the NHS improving clinical pathways and helping health systems to provide the best care and support to patients, added: “I have been pleased to collaborate with Jyoti to realise the potential of MIMOSA™ in supporting women and female individuals to understand and manage their unique menopause so that they can take control and keep living life to the full as they transition through it”

Wessex AHSN’s Insight team also provided expertise around designing evaluation studies, funding opportunities and bid preparations.

Sharma has spent 22 years designing and delivering large-scale people-centric organisational transformations across the Americas, Europe, Middle East and Africa. 

She was in her third year of individual differences in menopause research when she decided to found her start-up in May 2022, declining PhD offers from prestigious universities in England and Australia. 

“This felt like my life-long PhD,” Sharma explained. “I traded in the Dr title for the translation of our research with tech to deliver improved health for individuals, families, organisations and ultimately our society through this inevitable transition in a female individual’s life.”

After launching the first version of its proprietary Menopause Intelligence™ Maturity Index, Sharma and her team are now focusing on an equity seed investment round that she says will help fuel their rapid growth and expansion into the US and Canada.

MIMOSA™ is available on Android and iOS in India, England, Wales, Scotland, NorthernIreland, Vietnam, Uganda, Nigeria, Kenya, Germany, Switzerland, Austria, Netherlands, USA, UAE, SaudiArabia.

Adolescent health

Newly-launched Female Health Hub will support grassroots football players

Published

on

A new Female Health Hub launched by the English FA will support women and girls in grassroots football in England with trusted advice on health issues affecting play.

The hub brings together expert-backed guidance, practical tools and player insights in one place, giving women and girls practical advice and reassurance on female health in football.

It has four core aims: to help women and girls better understand their bodies and how female health affects performance and participation, to educate players on key health topics and when to seek further advice or support, to provide practical strategies to help navigate common female health challenges, and to help break down taboos and normalise conversations around female health in football.

Users of the hub will also be able to hear directly from members of the England women’s national team, who share their own experiences of navigating female health matters while playing at the highest level of the game.

“Our ambition is to create a game where women and girls can thrive,” said Sue Day, the FA’s director of women’s football.

“To achieve that, it’s essential that players feel supported in environments that understand and respond to their female health needs.

“We’ve heard directly from grassroots players that they want better information and support around female health, but that they often don’t know where to find it.

“The launch of the Female Health Hub marks an important step in changing the landscape.

“We want every player to feel confident in her own skin and supported without judgment, so she can feel empowered by her body, rather than held back by it.”

The platform was launched following research conducted by the FA that highlighted the need for better education and support around female health in football.

According to the FA, 88 per cent of adult players surveyed said their menstrual cycle has an impact on their ability to train or play, but 86 per cent reported they had never received education about the menstrual cycle in relation to football performance and training.

The research also found 64 per cent of women experience issues related to sports bras or breast health while playing football, despite sports bras being considered one of the most important pieces of playing kit.

Players also expressed strong interest in learning more about injury prevention, at 87 per cent, nutrition, at 84 per cent, and mental health, at 77 per cent, in relation to female health.

The first phase of the Female Health Hub focuses on three of the most requested topics: menstrual health, breast health and injury resilience, with further content to follow, including nutrition and pelvic health guidance.

Continue Reading

Pregnancy

Women’s health strategy a ‘missed opportunity,’ RCM says

Published

on

The Royal College of Midwives (RCM) has referred to the women’s health strategy as a ‘missed opportunity’ to address maternity services. 

The renewed strategy was released by the government this week, with the aim of putting women’s experiences at the centre of care and ensuring they are “better heard and served”.

However, the government stated that because of ongoing investigations into maternity services across the country, the strategy “does not seek to address safety in maternity and neonatal services”.

The RCM described this as a “missed opportunity” and urged the government to ensure that, following the inquiries, maternity is placed “at the very heart” of the strategy.

Gill Walton, RCM chief executive, said the college was “deeply disappointed” that maternity services “do not feature as a headline priority” in the renewed strategy.

She said: “This is a significant missed opportunity and one that is very difficult to understand.

“Pregnancy, birth and the postnatal period are not a footnote in women’s health – they are one of the most significant and consequential phases of a woman’s life.

“A strategy that treats maternity as an afterthought is not truly a women’s health strategy at all. It is exactly the kind of thinking that has allowed maternity services to reach the point they are at today.”

Walton acknowledged that the strategy contained commitments on ensuring women’s voices shape their care, on supporting families through pregnancy loss and on the principle that services should be held accountable when they fail to listen to women.

She added: “But a strategy that addresses one part of women’s health while leaving maternity care behind is only doing half the job.”

Walton urged the government to ensure that this is addressed when the ongoing investigations into maternity care conclude, with any recommendations placed “at the very heart of this strategy with the seriousness and urgency that women, families and midwives deserve”.

In the foreword to the renewed plans, health and social care secretary Wes Streeting referred to the ongoing independent National Maternity and Neonatal Investigation as action being taken by the government to improve safety in maternity services.

The strategy also refers to the new National Maternity and Neonatal Taskforce, chaired by Streeting, which aims to help deliver “safer, more equitable care” for women, babies and families.

The foreword said that, because of ongoing initiatives, it was “important that this work continues without restriction and that the government can properly respond to the findings”.

It added: “This renewed women’s health strategy therefore does not seek to address safety in maternity and neonatal services other than that related to women’s health before and during pregnancy and the actions we are taking immediately to improve maternity and neonatal care.”

The strategy does, however, include plans to prioritise health education in schools, communities and healthcare settings to “empower women” with the “knowledge and tools they need to help control their fertility” and “prepare for the best pregnancy outcomes.

It also promises to provide women with access to “safe and high-quality contraception, abortion care, fertility services, preconception care and support after pregnancy loss in convenient settings.

Continue Reading

Fertility

Genetic carrier screening before pregnancy: What to know

Published

on

Article produced in association with London Pregnancy Clinic and Jeen Health

For the majority of couples planning a pregnancy, genetic testing is not something they think about until a problem arises.

Pre-conception genetic carrier screening challenges this approach by identifying risk before pregnancy begins.

As panel sizes have grown and at-home testing options have become widely available, carrier screening is transitioning from a niche clinical referral into a mainstream component of reproductive planning.

What Carrier Screening Tests For

Being a carrier of a genetic condition means carrying one copy of a variant in a gene associated with that condition, without being affected by it.

In most cases, carriers are entirely unaware of their status.

The clinical significance of carrier status emerges when both members of a couple carry a variant in the same gene: in this scenario, each pregnancy carries a one in four chance of resulting in a child who inherits two copies of the variant and is affected by the condition.

The conditions most frequently included in expanded carrier screening panels include cystic fibrosis, spinal muscular atrophy (SMA), fragile X syndrome, sickle cell disease, and a range of metabolic and enzyme deficiency disorders.

The Beacon 787 carrier test, offered by Jeen Health, screens for 787 conditions from a single sample, making it one of the most comprehensive panels currently available to UK families.

Who Is Most Likely to Benefit

Any couple planning a pregnancy can consider carrier screening. It is particularly relevant for:

  • Couples with a family history of a known inherited condition
  • Those from populations with higher carrier frequencies for specific conditions, including Ashkenazi Jewish, South Asian and African communities
  • Couples pursuing fertility treatment, where genetic information informs treatment planning
  • Those who wish to have the most complete picture of their reproductive health before conception

Importantly, being a carrier of a condition does not mean a child will be affected. It means there is a defined statistical risk that can be quantified, discussed and planned for with appropriate clinical support.

How the Test Is Performed

Carrier screening is typically carried out on a blood or saliva sample.

For at-home options such as the testing offered by Jeen Health, a cheek swab collection kit is dispatched to the patient, the sample is returned by post, and results are delivered digitally within a defined turnaround period.

In-clinic carrier testing may use a blood draw and provides the advantage of immediate access to a clinical consultation at the point of result delivery.

London Pregnancy Clinic offers genetics counselling through its partnership with Jeen Health, allowing couples to receive and contextualise carrier test results with expert support.

Genetic counselling before and after testing is recommended by Genomics England as a standard component of any genomic testing pathway.

What Happens If Both Partners Are Carriers

If both partners are identified as carriers for the same autosomal recessive condition, they are typically offered further counselling to discuss their options.

These may include proceeding naturally with an awareness of the risk, using prenatal diagnosis (CVS or amniocentesis) during pregnancy to test the fetus, or pursuing preimplantation genetic testing (PGT) in the context of IVF, which allows unaffected embryos to be selected before transfer.

The purpose of identifying carrier status before pregnancy is to give couples time to consider these options without the added pressure of an ongoing pregnancy.

Knowledge of carrier status does not remove reproductive choices; it expands the information available when making them.

The Role of Pre-Conception Services

Carrier screening sits within a broader category of pre-conception care that includes fertility assessments, general health optimisation and, where relevant, management of existing conditions before pregnancy begins.

London Pregnancy Clinic offers pre-conception services encompassing fertility investigations, genetics counselling and carrier testing as part of an integrated 0th trimester approach, allowing couples to address genetic and clinical risk factors before their pregnancy starts rather than after.

Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.

Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.

This piece was produced in association with London Pregnancy Clinic and Jeen Health, which provided background clinical information for editorial purposes.

Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.